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ﺔﻴﻠﻛﺕﺎﺒﻟﺎﻃﻭﺏﻼﻄﻟﺔﻴﻋﺎﻨﻤﻟﺍﺔﻟﺎﺤﻟﺍﻰﻠﻋﻑﺮﻌﺘﻠﻟﺚﺤﺒﻟﺍﻑﺪﻬﻳ:ﺚﺤﺒﻟﺍﻑﺍﺪﻫﺃ
ﻚﻟﺫﻭﺔﻴﻋﺎﻨﻤﻟﺍﺔﺑﺎﺠﺘﺳﻻﺍﻒﻌﺿﻲﻓﺔﺒﺒﺴﺘﻤﻟﺍﺔﻴﺗﺍﺬﻟﺍﻞﻣﺍﻮﻌﻟﺍﻚﻟﺬﻛﻭ،ﺐﻄﻟﺍ
ﺪﻨﻋ"ﺏ"ﻱﺪﺒﻜﻟﺍﻲﺳﻭﺮﻴﻔﻟﺍﺏﺎﻬﺘﻟﻻﺍﺪﺿﺔﻋﺎﻨﻤﻟﺍﻦﻣﺭﺪﻗﺮﺒﻛﻷﻞﺻﻮﺘﻟﺍﺽﺮﻐﻟ
.ﻞﺒﻘﺘﺴﻤﻟﺍﺀﺎﺒﻃﺃﻭﻲﺤﺼﻟﺍﻝﺎﺠﻤﻟﺍﻲﻓﻦﻴﻠﻣﺎﻌﻟﺍ
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ﺕﺬﺧﺃﻚﻟﺬﻛﻭﺚﺤﺒﻟﺎﺑﺔﺻﺎﺨﻟﺍﺔﻧﺎﺒﺘﺳﻻﺍﺔﺌﺒﻌﺘﺑﺔﺒﻟﺎﻃﻭﺐﻟﺎﻃﻞﻛﻡﺎﻗﺚﻴﺣﺐﻄﻟﺍ
ﺔﻴﻋﺎﻨﻤﻟﺍﻡﺎﺴﺟﻷﺍﺔﺒﺴﻧﺔﻓﺮﻌﻤﻟﺎﻴﻠﻤﻌﻣﺎﻬﻠﻴﻠﺤﺗﻭﺔﺒﻟﺎﻃﻭﺐﻟﺎﻃﻞﻛﻦﻣﻡﺩﺔﻨﻴﻋ
."ﺏ"ﻱﺪﺒﻜﻟﺍﻲﺳﻭﺮﻴﻔﻟﺍﺏﺎﻬﺘﻟﻻﺍﻞﺋﻻﺩﻭ
ﻢﻬﻧﺃﺎﻣﺎﻤﺗﻥﻮﻛﺭﺪﻣﺕﺎﺒﻟﺎﻄﻟﺍﻭﺏﻼﻄﻟﺍﻦﻣ%٢.٦٣ﻥﺃﺞﺋﺎﺘﻨﻟﺍﺕﺮﻬﻇﺃ:ﺞﺋﺎﺘﻨﻟﺍ
ﺏﻼﻄﻟﺍﻦﻣ%٤.٢٥ﻭ،"ﺏ"ﻱﺪﺒﻜﻟﺍﻲﺳﻭﺮﻴﻔﻟﺍﺏﺎﻬﺘﻟﻻﺍﺪﺿﻢﻴﻌﻄﺘﻟﺍﺍﻭﺬﺧﺃﺪﻗ
ﻢﻬﻧﺃﻦﻴﻛﺭﺪﻣﺮﻴﻏ%٤.١١ﻥﺎﻛﺎﻤﻨﻴﺑ،ﻢﻴﻌﻄﺘﻟﺍﻢﻫﺬﺧﺃﻦﻣﻦﻳﺪﻛﺄﺘﻣﺮﻴﻏﺕﺎﺒﻟﺎﻄﻟﺍﻭ
ﻲﺋﺎﻗﻭﺭﺪﻗﻢﻬﻳﺪﻟﺏﻼﻄﻟﺍﻉﻮﻤﺠﻣﻦﻣﻂﻘﻓ%٢.٥١ﻥﺃﻦﻴﺒﺗﺎﻤﻛ.ﻢﻴﻌﻄﺘﻟﺍﺍﻭﺬﺧﺃﺪﻗ
ﻱﺃﺪﺟﻮﺗﻢﻟﺎﻤﻨﻴﺑ"ﺏ"ﻱﺪﺒﻜﻟﺍﻲﺳﻭﺮﻴﻔﻟﺍﺏﺎﻬﺘﻟﻼﻟﺔﻴﻋﺎﻨﻤﻟﺍﻡﺎﺴﺟﻷﺍﻦﻣﻑﺎﻛ
ﺩﻮﺟﻭﻦﻴﺑﺔﻴﺋﺎﺼﺣﺇﺔﻟﻻﺩﻭﺫﻁﺎﺒﺗﺭﺍﺩﻮﺟﻭﻦﻴﺒﺗﺎﻤﻛ.ﺔﻴﻘﺒﻟﺍﺪﻨﻋﺔﻴﻋﺎﻨﻣﻡﺎﺴﺟﺃ
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Abstract
Objectives: This study aimed to determine the immune
status of TaibahUniversitymedical students againstHBV,
and the possible host factors related to the poor response to
a previously-administered hepatitis-B vaccine.
Methods: A cross-sectional study was conducted which
included all 3rd year medical students of Taibah Uni-
versity. One hundred and five responded to a self-
administered questionnaire. At the same time, a blood
sample analysis was performed for hepatitis B markers
(HBs Ag, HBcAb, and HBs Ab) of the participants.
Results: Of the total number of respondents, only 36.2%
were aware that they received a hepatitis-B vaccine,
52.4% were not sure they received it, and 11.4% were not
aware of receiving it. Of all, the hepatitis B markers
showed that only 16 students (15.2%) had protective
levels against the disease, while the rest showed negative
markers, and only one student was immune due to past
infection. Students with protective titers often had a
family history for hepatitis B or a positive history of
contact with a known case.
Conclusion: The low prevalence of HBV protective levels
in Taibah University medical students needs further
research and mandates implementation of a screening
M. Mosaad et al.302program and vaccination for all non-immune health care
students.
Keywords: Antibodies; Hepatitis B virus; Immunization in
Kingdom of Saudi Arabia; Low immunity
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Hepatitis B is a major public health problem. Approxi-
mately 30% of the world’s population, i.e. about 2 billion
people, have serological evidence of infection with hepatitis
B virus (HBV), of which 350 million have chronic HBV
infection, of which about a million die each year from
chronic liver disease, including cirrhosis and liver cancer
(HBV being second to tobacco as a known human carcin-
ogen).1 In areas of intermediate endemicity, the lifetime risk
of HBV infection is 20e60%. Infections occur in all age
groups where acute hepatitis B is common in these areas
because many infections occur in adolescents and adults.2,3
Another fact that HBV infection is endemic in Kingdom of
Saudi Arabia is that between 7% and 8% of apparently
healthy adults in the Saudi population are HBs Ag carriers,
and at least one hepatitis B marker is positive in 60% to
70% of the population. Also, virus transmission occurs
mainly horizontally and early in life within the Saudi
population4 in spite of the facts that in 1990 the national
strategy to eliminate hepatitis B virus (HBV) infection in
Kingdom of Saudi Arabia included universal
administration of HBV vaccine to all infants and that from
1990 to 1995 this vaccine was also routinely administered
to children at school entry. In fact, some studies still
confirm that HBV is a common health problem with
increased prevalence.5,6 Universal immunization beginning
at birth, however, in addition to other successful hepatitis
B vaccination strategies, has resulted in a dramatic
reduction of HBV transmission in many countries with
historically high endemicity.7 But the response to the
vaccine must be followed up as studies showed varied
response. Also, the need for catch-up vaccination in age
groups older than one year should be assessed, where it varies
depending on the endemicity of HBV infection in particular
countries.2,8 Medical students during their clinical training
years should be considered as having the same high risk as
health care workers for catching HBV infection, and
should be protected before starting their clinical years.
The research is an attempt to determine the immune
status of the medical students at Taibah University, to
determine the possible host factors related to the poor
response to previously administered hepatitis B vaccine, and
to identify those who need vaccination, re-vaccination, or
booster dose.
Materials and Methods
Study design: A descriptive cross-sectional study was used.
Research sitting: Faculty of Medicine, Taibah University
and King Fahd Hospital in Almadinah Almunawwarah.Target population: All Taibah University 3rd-year med-
ical students who accepted to participate in the study before
starting their clinical training in the affiliated hospitals (105
students out of 122) including 46 males and 59 females.
Research tools:
1- Self-administered questionnaire:
Data were collected through pre-designed self-adminis-
tered questionnaire. The validity and reliability of the ques-
tionnaire (Appendix No. 1) was tested through a pilot study
and discussions with public health and internal medicine
experts. Then 12 students (10%) from the 3rd year
medical student were randomly selected to explore if there
is any ambiguity or items leading to misunderstanding
in the questionnaire in order to reach to its current final form.
2- Investigations:
Four milliliters of whole blood was collected from each
subject at out-patients lab at King Fahd Hospital. Then the
sera was separated and frozen at 20 C until tested. HBs
Ab, HBs Ag, and HBcAb were determined by an enzyme-
linked immunosorbent assay (ELISA) using a commer-
cially available kit (Biokit, S.A., Barcelona, Spain).Data interpretations
- Those who had been vaccinated before and had HBs
Abtitre >10 iu/ml were considered immune and had a
protective titer.
- Those who had been vaccinated before and had HBs
Abtitre<10 iu/ml were considered lacking a protective titer
and needed a booster dose and follow-up after that.
- Those who tested HBcAb positive and had no vaccination
history were considered to have a past infection.
- Those who tested HBcAb positive and HBs Ab positive
with no history of vaccination were considered to be im-
mune due to a past infection.
- Those who tested HBs Abis negative and had no vaccina-
tion history were considered not immune and needed
vaccination.Data analysis
The collected data was statistically managed by SPSS
software version 17. Chi-square (c2) was used to statistically
test significant differences between the qualitative variables
and student t test in quantitative variables. The significance
level was accepted if the p value was 0.05.Ethical and administrative considerations
 A formal approval was taken from the Research Ethics
Committee in the Internal Medicine Department.
 A formal approval was taken from the King Fahad Hos-
pital Administrator to facilitate the study.
 Oral, free and informed consent was taken from each
student to participate in the research.
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Figure 2: Immune status among studied subjects.
Hepatitis B immunity in Taibah medical students 303Results
Among our study subjects (105 medical students), 46 were
males (43.8%) and 59 were females (56.2%); mean age was
21.77  0.9. Ninety-nine of the students lived in urban areas
(94.3%) and only six (5.7%) lived in rural areas; and while 99
were single (94.3%), six were married (5.7%). According to
their history 5 (4.8%) had family history of hepatitis B, 9
(8.6%) had a contact with a known case of hepatitis B, 13
(12.4%) had a history of hospitalizations, 9 (8.6%) had
previous operations, one (0.9%) had blood transfusion, and
six (5.7%) experienced dental procedures.
As regards the hepatitis B vaccination awareness history,
only 36.2% of our students were aware they received hepa-
titis B vaccine, 52.4% were not sure they received it, while 12
(11.4%) were not aware they received it (Figure 1). The
hepatitis markers showed that only 16 (15.2%) had HBs
Ab > 10 iu/ml while it was not detected in the rest (84.8%)
(Figure 2). Only one (0.9%) had HBcAb þve (plus HBs
Ab) with no sure history of vaccination, and no one had
HBs Ag in their serum.
(Table 1) shows that males constitute 25% of those with
protective titer, versus 47.2% for those with non-protective
titer. On the other hand, females constitute 75% and
56.2% respectively. All the students with protective titer
lived in urban areas, and 25% had positive family history for
hepatitis B, versus 1.1% for those with non-protective titer,
which was statistically significant. Also, 31.3% of those with
protective titer had a contact with cases of Hepatitis B, versus
17.4% for the others, which was statistically significant too.
(Table 2) shows that no one with a protective titer had any
chronic illness, versus 4.5% of those with non-protective
titer. Also, out of those with protective titer, 18.75% had a
history of hospitalization, where 18.7% underwent surgical
operations, 6.2% received blood transfusions, 12.5% had
dental procedures, and 26.6% were using common shaving
instruments, versus 11.2%, 6.7%, 0%, 4.5%, and 9% for
those with non-protective titer, respectively; however, all
these figures were statistically insignificant.
Discussion
This study was conducted among the 3rd year medical
students at Taibah University, Kingdom of Saudi Arabia,0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
vaccinated not vaccinated unsure
36.20%
11.40%
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Figure 1: Vaccination awareness status among studied subjects
according to history.before starting their first clinical training in the hospitals. It
aimed to find out their immune status for Hepatitis B virus,
the host factors behind the poor response for vaccination,
and determine the next step for every one as regards the
need for vaccination, re-vaccination, or booster dose. Being
a country of intermediate prevalence for hepatitis B,4
Kingdom of Saudi Arabia has included universal
administration of HBV vaccine to all infants since 1990.
From 1990 to 1995 this vaccine was also routinely
administered to children at school entry.9 Moreover, the
authorities did not give any child their official birth
certificate at that time until they got all the mandatory
vaccines, including hepatitis B. So, we were sure that all
our students received the vaccine. Surprisingly, however,
when we asked the study subjects about their awareness
of being vaccinated or not, only 36.2% were sure that
they received the vaccine, 52.4% not aware if they
received the vaccine and 11.4% recalled that they did not
receive it at all! This may reflect a lack of awareness about
such subject for the future doctors, or the presence of
technical and/or social factors, which prevented the
complete coverage of the whole target population in
1990.9,10 However, this is still better than the results in
one study in Cameron, which showed that only 18% of
the medical students were adequately vaccinated, 30.6%
inadequately vaccinated and 51.4% did not receive the
vaccine.11 Also, in Nigeria the coverage was 47.7% in
medical students12 and 37.9% among dental students.13
Not only were these disappointing results restricted to
medical students alone, but generally the health care
workers vaccination coverage was low in other studies in
Pakistan (37.2%),14 South Africa (19.9),15 and Egypt
(15.8%),16 whereas the vaccination coverage was 76.6%
among the medical students and 46.7% among interns in
Palestine,12 and another high coverage (80.5%) reported
among dentists in a recent study in KSA.17
As regards the immune status in our students, only 15.2%
proved to have protective titer with their HBs Ab> 10 iu/ml.
A possible interpretation is that the antibody titer declined
significantly with time. In addition, 5e10% of the vaccinated
subjects shows low antibody titer beside 3e20% known
failure rate, which can be attributed to vaccine factors (e.g.
type, dose, schedule and injection site ) or host factors (e.g.
old age, male sex, obesity, smoking, and chronic illness).18e20
However, the cases where the subjects were vaccinated and
had low or undetected titer cannot be interpreted as having
vaccine failure for two main reasons: first, to prove vaccine
failure we have to do post-vaccination testing 1e2 months
after completion of the three doses of the vaccine; second,
we did not explore their memory cells to show if they still
Table 1: Immune status among studied subjects according to their personal and medical history.
Variable Protective titer Non-protective titer Total P value
N ¼ 16 N ¼ 89
NO. % NO. %
Age (mean ± SD) 21.8  1.22 21.7  0.83 21.77  0.9 0.84
Sex
Male 4 25 42 47.2 46 43.8
Female 12 75 47 52.8 59 56.2 0.10
Residence
Urban 16 100 83 93.3 99 94.3
Rural 0 0 6 6.7 6 5.7 0.28
Family history of HBV
+ve 4 25 1 1.1 5 4.8
ve 12 75 88 98.9 100 95.2 0.00*
Case contact with HBV
+ve 5 31.3 4 17.4 9 8.6
ve 11 68.7 85 82.6 96 91.4 0.00*
*Significant P value.
M. Mosaad et al.304had anti-HBs antibody-secreting cells as shown in some
studies.21,22
Another important point in our study is that we did not
find any statistical significant difference between those with
the protective titer and the others with the non-protective.
However, there are interesting, statistically-significant
findings; subjects with protective titers often had a family
history for hepatitis B and positive contact with a known
case of hepatitis B. This can be interpreted as follows: such
subjects might have a chance for acquiring interfamilial
hepatitis antigen or getting it from contacts, which might
have stimulated their memory cells and kept the titer high.
Another finding is that the vaccinated group with a non-
protective titer had more frequent chronic illnesses
compared to those with a protective titer, which is one ofTable 2: Immune status among studied subjects according to their m
Variable Students with protective titer Students wi
N ¼ 16 N ¼ 89
NO. % NO.
Have chronic illness
Yes 0 0 4
No 16 100 85
History of hospitalization
Yes 3 18.7 10
No 13 81.3 79
Surgical operations
Yes 3 18.7 6
No 13 81.3 83
Blood transfusion
Yes 1 6.2 0
No 15 93.8 89
Dental procedures
Yes 2 12.5 4
No 14 87.5 85
Using common shaving instruments
Yes 4 26.6 8
No 12 73.4 81the reported causes of vaccine failure.18,19 However, these
results need to be re-evaluated on a larger sample size.
Therefore, to achieve our ultimate goal for maximum
protection among our future healthcare workers, we advised
those who did not receive the vaccine to take vaccination,
and those who had non-protective titer and previous
vaccination to receive one dose of hepatitis B vaccine and
test for antibodies titer after 4e6 weeks. Then if the titer was
more than 10 iu/ml, this means a booster dose response in a
previously vaccinated person, and if not, they would have to
receive two more doses to complete the vaccination. After
that, if (what: titer?) is still <10 iu/ml or not detected, this
means true vaccine failure and this person should consider
post exposure management if he/she were accidently infec-
ted with hepatitis B virus during work. Moreover, weedical and surgical hazards.
th non-protective titer Total P value
% NO. %
4.5 4 3.8
95.5 101 96.2 0.51
11.2 13 12.4
88.8 93 87.6 0.40
6.7 9 8.6
93.3 96 91.4 0.11
0 1 1
100 104 99 0.15
4.5 6 5.7
95.5 99 94.3 0.20
9 12 11.4
91 93 88.6 0.66
Hepatitis B immunity in Taibah medical students 305recommend that Taibah University and other health in-
stitutes, which graduate all health care workers, screen for
hepatitis B antibody titer in their students before they are
exposed to real clinical work, and adopt our protocol in
management. However, some suggested that this screening
is not cost-effective,19 but we believe that it would be cost-
effective in a moderate endemic area with such a diseases
with high morbidity and mortality, and mostly need long life
treatment in chronically infected patients.
Conclusion
Only small number of our medical students at Taibah
University had protective levels of antibodies against HBV.
Consequently, we recommend applying more studies and
surveillance for all our future health care workers to ensure
their protection against hepatitis B, which is still prevalent
and causes significantmorbidity andmortality in our country.
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